Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab in persistent moderate to severe atopic dermatitis (TREBLE)
NCT02340234Phase 2Completed
- Sponsor
- Roche
- Start
- May 2015
- Primary completion
- Apr 2016
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of lebrikizumab in atopic dermatitis (AD) (4 arms), sponsored by Roche. Primary endpoint: Percentage of Participants Achieving a 50 Percent Reduction From Baseline in Eczema Area and Severity Index Score at 12 weeks. Started May 2015; status: completed.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02340234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02340234.